IL230447A - Salts of aza-bicyclic di-aryl ethers and methods to make them or their precursors - Google Patents

Salts of aza-bicyclic di-aryl ethers and methods to make them or their precursors

Info

Publication number
IL230447A
IL230447A IL230447A IL23044714A IL230447A IL 230447 A IL230447 A IL 230447A IL 230447 A IL230447 A IL 230447A IL 23044714 A IL23044714 A IL 23044714A IL 230447 A IL230447 A IL 230447A
Authority
IL
Israel
Prior art keywords
aza
bicyclic
precursors
salts
methods
Prior art date
Application number
IL230447A
Other languages
Hebrew (he)
Other versions
IL230447A0 (en
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45478332&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL230447(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of IL230447A0 publication Critical patent/IL230447A0/en
Publication of IL230447A publication Critical patent/IL230447A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/41—Preparation of salts of carboxylic acids
    • C07C51/412—Preparation of salts of carboxylic acids by conversion of the acids, their salts, esters or anhydrides with the same carboxylic acid part
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/08—Malonic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/10—Succinic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/145—Maleic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/15—Fumaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Addiction (AREA)
  • Gynecology & Obstetrics (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
IL230447A 2011-07-15 2014-01-13 Salts of aza-bicyclic di-aryl ethers and methods to make them or their precursors IL230447A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161508147P 2011-07-15 2011-07-15
PCT/EP2012/063712 WO2013010916A1 (en) 2011-07-15 2012-07-12 Salts of aza-bicyclic di-aryl ethers and methods to make them or their precursors

Publications (2)

Publication Number Publication Date
IL230447A0 IL230447A0 (en) 2014-03-31
IL230447A true IL230447A (en) 2017-02-28

Family

ID=45478332

Family Applications (2)

Application Number Title Priority Date Filing Date
IL230447A IL230447A (en) 2011-07-15 2014-01-13 Salts of aza-bicyclic di-aryl ethers and methods to make them or their precursors
IL250353A IL250353A0 (en) 2011-07-15 2017-01-30 Salts of aza-bicyclic di-aryl ethers and methods to make them or their precursors

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL250353A IL250353A0 (en) 2011-07-15 2017-01-30 Salts of aza-bicyclic di-aryl ethers and methods to make them or their precursors

Country Status (27)

Country Link
US (3) US9365565B2 (en)
EP (2) EP3075732B1 (en)
JP (2) JP6263469B2 (en)
KR (3) KR101846770B1 (en)
CN (2) CN103717596B (en)
AR (1) AR087164A1 (en)
AU (1) AU2012285943B2 (en)
BR (1) BR112014000907A2 (en)
CA (1) CA2841546C (en)
CL (1) CL2014000119A1 (en)
CO (1) CO6852078A2 (en)
EA (1) EA025477B1 (en)
ES (1) ES2611950T3 (en)
GT (1) GT201400007A (en)
HK (2) HK1194069A1 (en)
HU (1) HUE031256T2 (en)
IL (2) IL230447A (en)
JO (1) JO3249B1 (en)
MA (1) MA35263B1 (en)
MX (2) MX348306B (en)
MY (1) MY173454A (en)
PE (1) PE20141939A1 (en)
SI (1) SI2731946T1 (en)
TN (1) TN2013000530A1 (en)
TW (1) TWI589576B (en)
UA (1) UA113409C2 (en)
WO (2) WO2013010679A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6263469B2 (en) * 2011-07-15 2018-01-17 ノバルティス アーゲー Salt of azabicyclic di-aryl ether and method for producing the same or method for producing the precursor
EP3251673A1 (en) 2012-12-13 2017-12-06 IP Gesellschaft für Management mbH Combination therapy comprising a cdk4/6 inhibitor and a pi3k inhibitor for use in the treatment of cancer
CN103601748B (en) * 2013-10-17 2016-11-02 上海交通大学 Hydroxyalkylation heterocyclic boronic acids ester and preparation method thereof, purposes
WO2017201364A1 (en) * 2016-05-20 2017-11-23 Vanda Pharmaceuticals Inc. Method for improving or enhancing cognition
WO2018165145A1 (en) * 2017-03-08 2018-09-13 Ariad Pharmaceuticals, Inc. Pharmaceutical formulations comprising 5-chloro-n4-[2-(dimethylphosphoryl) phenyl]-n2-{2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl} pyrimidine-2,4-diamine
EP3700530B1 (en) 2017-10-26 2023-04-19 Xynomic Pharmaceuticals, Inc. Crystalline salts of a b-raf kinase inhibitor
KR20220016949A (en) 2019-06-06 2022-02-10 젠플리트 테라퓨틱스 (상하이) 아이엔씨. Polymorphisms of CDK9 inhibitors and their preparation and use
US20230381169A1 (en) 2020-11-25 2023-11-30 Vanda Pharmaceuticals Inc. Treatment of public speaking anxiety with an alpha-7 nicotinic acetylcholine receptor agonist

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4605652A (en) 1985-02-04 1986-08-12 A. H. Robins Company, Inc. Method of enhancing memory or correcting memory deficiency with arylamido (and arylthioamido)-azabicycloalkanes
US4863919A (en) 1988-02-01 1989-09-05 A. H. Robins Company, Incorporated Method of enhancing memory or correcting memory deficiency with arylamido(and arylthiomido)-azabicycloalkanes
SE0000540D0 (en) 2000-02-18 2000-02-18 Astrazeneca Ab New compounds
AR031130A1 (en) 2000-09-20 2003-09-10 Abbott Lab PROMOTING N-ACILSULFONAMIDS OF APOPTOSIS
AU2003302218A1 (en) 2002-05-16 2004-06-18 Genelabs Technologies, Inc Aryl and heteroaryl compounds as antibacterial and antifungal agents
SE0201544D0 (en) * 2002-05-17 2002-05-17 Biovitrum Ab Novel compounds and thier use
GB0220581D0 (en) 2002-09-04 2002-10-09 Novartis Ag Organic Compound
GB0415746D0 (en) * 2004-07-14 2004-08-18 Novartis Ag Organic compounds
JP2008523058A (en) * 2004-12-10 2008-07-03 アボット・ラボラトリーズ Fused bicycloheterocyclic substituted quinuclidine derivatives
FR2884516B1 (en) 2005-04-15 2007-06-22 Cerep Sa NPY ANTAGONISTS, PREPARATION AND USES
EA200901381A1 (en) 2007-05-10 2010-06-30 Пфайзер Лимитед AZETIDINE DERIVATIVES AND THEIR APPLICATION AS ANTAGONISTS OF PROSTAGLANDIN E2
RU2010101611A (en) * 2007-06-21 2011-07-27 Шеринг Корпорейшн (US) POLYCYCLIC DERIVATIVES OF GUANINE AND WAYS OF THEIR APPLICATION
US20090285774A1 (en) 2008-05-15 2009-11-19 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
CA2761858A1 (en) 2009-05-15 2010-11-18 Novartis Ag 5-pyridin-3-yl-1,3-dihydro-indol-2-on derivatives and their use as modulators of aldosterone synthase and/or cyp11b1
NZ596304A (en) 2009-05-28 2014-01-31 Novartis Ag Substituted aminopropionic derivatives as neprilysin inhibitors
CN102573842A (en) * 2009-07-23 2012-07-11 诺瓦提斯公司 Use of azabicycloalkyl derivatives or pyrrolidine-2-one derivatives
US8163704B2 (en) 2009-10-20 2012-04-24 Novartis Ag Glycoside derivatives and uses thereof
MX2012004707A (en) 2009-10-21 2012-06-08 Glaxo Group Ltd Process for preparing a phenylalanine derivative.
JP6263469B2 (en) * 2011-07-15 2018-01-17 ノバルティス アーゲー Salt of azabicyclic di-aryl ether and method for producing the same or method for producing the precursor
EP2931315B1 (en) * 2012-12-11 2017-11-29 Novartis AG Biomarker predictive of responsiveness to alpha 7 nicotinic acetylcholine receptor activator treatment
US20150313884A1 (en) * 2013-01-15 2015-11-05 Novartis Ag Use of alpha 7 nicotinic acetylcholine receptor agonists

Also Published As

Publication number Publication date
JP2014520824A (en) 2014-08-25
UA113409C2 (en) 2017-01-25
IL230447A0 (en) 2014-03-31
EP3075732A3 (en) 2017-01-04
ES2611950T3 (en) 2017-05-11
EA025477B1 (en) 2016-12-30
MX2014000619A (en) 2014-02-27
TWI589576B (en) 2017-07-01
CN107602552A (en) 2018-01-19
MY173454A (en) 2020-01-26
CA2841546A1 (en) 2013-01-24
JP2016185963A (en) 2016-10-27
JO3249B1 (en) 2018-09-16
AR087164A1 (en) 2014-02-26
CO6852078A2 (en) 2014-01-30
HK1249505A1 (en) 2018-11-02
EP2731946B1 (en) 2016-09-14
US20160145253A1 (en) 2016-05-26
MA35263B1 (en) 2014-07-03
NZ619574A (en) 2015-12-24
JP6355676B2 (en) 2018-07-11
MX348306B (en) 2017-06-06
CA2841546C (en) 2020-01-14
CN103717596B (en) 2017-11-21
GT201400007A (en) 2015-02-19
MX359856B (en) 2018-10-12
HUE031256T2 (en) 2017-06-28
IL250353A0 (en) 2017-03-30
EP3075732B1 (en) 2018-09-12
EP2731946A1 (en) 2014-05-21
AU2012285943A1 (en) 2014-01-23
KR20180037310A (en) 2018-04-11
US20140220125A1 (en) 2014-08-07
US10421755B2 (en) 2019-09-24
EA201490283A1 (en) 2014-06-30
HK1194069A1 (en) 2014-10-10
JP6263469B2 (en) 2018-01-17
KR101846770B1 (en) 2018-04-09
EP3075732A2 (en) 2016-10-05
TW201302740A (en) 2013-01-16
US9365565B2 (en) 2016-06-14
KR20140034309A (en) 2014-03-19
US9802931B2 (en) 2017-10-31
BR112014000907A2 (en) 2017-06-13
TN2013000530A1 (en) 2015-03-30
CN103717596A (en) 2014-04-09
SI2731946T1 (en) 2017-04-26
KR20170002699A (en) 2017-01-06
CL2014000119A1 (en) 2014-07-25
PE20141939A1 (en) 2014-12-05
WO2013010679A1 (en) 2013-01-24
US20180009801A1 (en) 2018-01-11
AU2012285943B2 (en) 2016-03-17
WO2013010916A1 (en) 2013-01-24

Similar Documents

Publication Publication Date Title
HK1249505A1 (en) Salts of aza-bicyclic di-aryl ethers and methods to make them or their precursors
HK1197068A1 (en) Methods for preparation of glycosphingolipids and uses thereof
ZA201400377B (en) Systems and methods for optimizing fit of implant to anatomy
EP2758932A4 (en) Methods and systems to share media
PL2761083T3 (en) Paper and methods of making paper
EP2672820A4 (en) Mannoside compounds and methods of use thereof
ZA201303433B (en) Inhibitors of hiv replication
EP2675471A4 (en) Hsa-related compositions and methods of use
ZA201401653B (en) Pyrazol-4yl-heterocyclyl-carboxamide compounds and methods of use
EP2704688A4 (en) Cochleate compositions and methods of making and using same
IL235617A0 (en) Use of seaprose to remove bacterial biofilm
EP2548859A4 (en) Preparation methods of methyl-d3-amine and salts thereof
EP2702034A4 (en) Preparation of fingolimod and its salts
IL227924B (en) Compositions and methods of use for determination of he4a
EP2706845A4 (en) Antimicrobial solid and methods of making and using same
EP2760992A4 (en) Use of hemopexin to sequester hemoglobin
EP2709999A4 (en) Quinazoline-7-ether compounds and methods of use
EP2922413A4 (en) Compostions of low sodium salt and methods of making and using
EP2670245A4 (en) Alpha-ketoheterocycles and methods of making and using
GB201117482D0 (en) Targetiing of miRNA precursors
EP2663574A4 (en) Inhibitors of retroviral replication
ZA201207945B (en) Salts of dexlansoprazole and their preparation
EP2684869A4 (en) Preparation of 3-mercaptopropionates
HUP1000638A2 (en) Process for preparation of rosuvastatin salts
EP2701712A4 (en) Use of uridine and deoxyuridine to treat folate-responsive pathologies

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed